UnitedHealth Stock Rebounds 59% on Strong Q1

UnitedHealth Stock Rebounds 59% on Strong Q1
UnitedHealth has surged 59% following robust first-quarter results and raised earnings guidance, earning a slim Buy rating from analysts. The healthcare giant's performance reflects investor confidence in its operational execution and capital allocation strategy through share buybacks. However, significant headwinds remain on the horizon. Department of Justice scrutiny over pharmacy benefit management practices presents material regulatory risk that could impact margins and profitability. The PBM business segment faces increasing political and legal pressure regarding drug pricing transparency and middleman fees. While the stock's recent rebound is impressive, investors should carefully weigh the strong fundamentals against mounting DOJ risks before adding positions.